Asthma is a chronic inflammatory disease of the airways that causes recurrent episodes of wheeze, breathlessness, chest tightness, and cough. Symptoms can vary over time and are often triggered by allergens, infections, exercise, or irritants.
FDA approved AstraZeneca's Breztri Aerosphere for asthma; EU CHMP recommended Trixeo. Phase 3 KALOS/LOGOS trials showed improved lung function and reduced severe exacerbations versus dual therapy.
A real-world study in Galicia showed nirsevimab reduced RSV-related hospitalizations by 85.9% in the first season and 55.3% in the second. The RSV prevention market is expanding to cover high-risk children, with Beyfortus the only antibody approved for second-season use. The FDA has cited Sanofi for misleading promotional claims about the product.
AstraZeneca published a large-scale CNV analysis in Nature and partnered with Helix for clinico-genomic data. Quotient Therapeutics is using somatic genomics to identify disease-relevant mutations.
Studies reveal how kinin receptor antagonists achieve subtype selectivity and identify BDNF as a direct TLR4 antagonist, highlighting BDP-12 as a potential therapy for acute inflammatory diseases.
Sanofi announces leadership transition with CEO departure and interim appointment, while reporting key regulatory milestones including FDA Breakthrough Therapy designation for venglustat and expanded Dupixent approvals. The company advances an observational RSV study in Australia and outlines strategic initiatives in AI drug discovery and potential consumer healthcare spin-off.
Kymera Therapeutics presented Phase 1 data for oral STAT6 degrader KT-621 in healthy Japanese adults, showing ≥98% STAT6 degradation and favorable safety. Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing with data expected in 2027, and FDA has granted Fast Track designation for both indications.
Recent research identifies hidden systemic inflammation in primary ciliary dyskinesia via oral swab and confirms asthma biologics do not increase respiratory infection risk in pediatric patients.
Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.
Altesa BioSciences reported positive Phase 2a challenge study results for vapendavir, an oral rhinovirus capsid inhibitor, showing reduced viral load and inflammation in COPD patients infected with rhinovirus. The data support vapendavir's potential to prevent rhinovirus-driven COPD exacerbations, and the company has initiated a Phase 2b CARDINAL trial to further evaluate the treatment.
A placebo-controlled trial shows tezepelumab significantly reduces oral corticosteroid dependence in severe asthma, with patients achieving nearly three times the odds of reduction versus placebo. A separate case report documents dramatic functional recovery in an elderly patient who switched from mepolizumab to tezepelumab after inadequate response.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07746687 |
A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07746570 |
SU JOK THERAPY TO IMPROVE DYSPNEA AND INSOMNIA IN ASTHMA |
COMPLETED | NA |
| NCT07733635 |
Vitamin D Status and Asthma Control, Pulmonary Function, and Oxidative Stress in Adults With Bronchial Asthma |
NOT_YET_RECRUITING | |
| NCT07728578 |
Effect of Pilates Training Versus High Intensity Interval Training on Cardiorespiratory Fitness in Asthmatic Patients |
NOT_YET_RECRUITING | NA |
| NCT07712393 |
A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283 |
RECRUITING | PHASE1 |
| NCT07675044 |
Quantifying the Burden of Type 2 (T2) Inflammation in Asthma |
NOT_YET_RECRUITING | |
| NCT07671001 |
A Study of Depemokimab in Participants of 6 to 11 Years of Age |
NOT_YET_RECRUITING | PHASE3 |
| NCT07666490 |
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg]) |
RECRUITING | PHASE4 |
| NCT07664527 |
Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate |
NOT_YET_RECRUITING | PHASE4 |
| NCT07660731 |
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma |
RECRUITING | PHASE1 |
